Nobivac® Feline 1-HCPCh + FeLV vaccine is a combination vaccine that unites the benefits of Nobivac® Feline 1-HCPCh and Nobivac® FeLV in one vaccination.
Nobivac® Feline 1-HCPCh vaccine is a modified live virus and chlamydia vaccine for the vaccination of healthy cats as an aid in the prevention of disease caused by feline rhinotracheitis, calici, and panleukopenia viruses and Chlamydia psittaci.
Nobivac® FeLV vaccine is recommended for the vaccination of healthy cats as an aid in the prevention of lymphoid tumors caused by, and diseases associated with, feline leukemia virus (FeLV) infection. Vaccination with this product prevents persistent viremia in cats exposed to virulent feline leukemia virus.
The feline leukemia virus, subgroups A and B, are cultured in tissue culture cells. The virus has been chemically inactivated and combined with a proprietary adjuvant designed to enhance the immune response.
DOSAGE AND ADMINISTRATION:
Prior to use, warm the Nobivac® FeLV to room temperature and shake well.
Transfer contents of the Nobivac® FeLV vial to the Nobivac® Feline 1-HCPCh vial aseptically. Mix gently until dissolved. Use entire contents immediately after rehydration.
Two doses are required for primary immunization.
Initial vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly at 9 weeks of age or older.
Second vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination.
Revaccinate every two years with a single dose of Nobivac® Feline 1-HCPCh+FeLV. Revaccination in the intervening years with Nobivac® Feline 1-HCPCh is recommended. Following the advice of the American Veterinary Medical Association on Vaccination Principles, an appropriate revaccination program for individual animals should be made based upon veterinarian-client-patient relationships.
Do not vaccinate pregnant cats.
Click here for our Vaccine Shipping Schedule.